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  Enterohemorrhagic Escherichia coli serotype O157:H7 is 
a pathotype of diarrheagenic E. coli that produces one or 
more Shiga toxins, forms a characteristic histopathology 
described as attaching and effacing lesions, and possesses 
the  large  virulence  plasmid  pO157.  The  bacterium  is 
recognized worldwide, especially in developed countries, 
as  an  emerging  food-borne  bacterial  pathogen,  which 
causes disease in humans and in some animals. Healthy 
cattle  are  the  principal  and  natural  reservoir  of  E.  coli 
O157:H7, and most disease outbreaks are, therefore, due 
to  consumption  of  fecally  contaminated  bovine  foods  or 
dairy  products.  In  this  review,  we  provide  a  general 
overview of E. coli O157:H7 infection, especially focusing 
on  the  bacterial  characteristics  rather  than  on  the  host 
responses during infection.
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Escherichia coli
  Escherichia ( E.)  coli  was first described in 1885 by 
Theodore Escherich as a pure culture of slim, occasionally 
slightly curved, and short rods ranging in size from 1-5 μm 
in length and 0.3-0.4 μm in thickness [9]. As a part of the 
normal gut microflora, this microorganism colonizes the 
gastrointestinal tract of warm-blooded animals and 
humans within a few hours after birth and plays an 
important role in maintaining gut physiology [9,35]. 
However, some E. coli strains have acquired specific 
virulence factors by means of mobile genetic elements 
such as plasmids, transposons, bacteriophages, and 
pathogenicity islands, and have evolved into pathogenic E. 
coli [64]. 
  Based on their common clinical features, pathogenic E. 
coli are categorized into (i) diarrheagenic E. coli, (ii) 
uropathogenic E. coli, (iii) meningitis/sepsis-associated E. 
coli, and (iv) avian pathogenic E. coli [64,93]. Diarrhea-
genic E. coli can be further categorized into six well- 
described pathotypes based on virulence properties, 
pathogenic mechanisms, clinical syndromes, and distinct 
serogroups/serotypes: (i) enterotoxigenic E. coli (ETEC), 
(ii) enteropathogenic E. coli (EPEC), (iii) enterohemorrhagic 
E. coli (EHEC), (iv) enteroaggregative E. coli (EAEC), (v) 
enteroinvasive E. coli (EIEC), and (vi) diffusely adherent 
E. coli (DAEC). These pathotypes of E. coli seem to be 
clonal groups that have shared O and H antigens [64,93].
  The ETEC cause infantile diarrhea, traveler’s diarrhea in 
developing countries, and diarrhea in very young animals, 
such as piglets, lambs, and calves [35,93]. The micro-
organism colonizes the surface of the small intestinal 
mucosa using one or more adhesive fimbriae and produces 
enterotoxins, heat-labile enterotoxin (LT), and/or heat- 
stable enterotoxin (ST) [20,93,119]. The most frequent 
ETEC serogroups include O6, O8, O15, O20, O25, O27, 
O63, O78, O85, O115, O128ac, O148, O159, and O167 
[35]. People are the principal reservoir of ETEC that cause 
human illness [35,93].
  The EPEC cause epidemic and sporadic infantile diarrhea 
in developing countries [35,78,93]. This microorganism 
produces a characteristic intestinal histopathology called 
attaching and effacing (A/E) lesions, in which bacteria 
intimately attach to the intestinal epithelial cells and 
rearrange the cytoskeletal actin underneath [35,78,93]. A 
three-stage model of pathogenesis has been proposed that 
includes localized adherence, signal transduction, and 
intimate adherence [32,33]. The most frequent EPEC 
serogroups implicated in human disease include O55, O86, 
O111ab, O119, O125ac, O126, O127, O128ab, and O142 
[35]. People are the principal reservoir of EPEC that cause 
human illness [35,93].
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adults worldwide [35,93]. By definition, this micro-
organism does not produce LT or ST, but has a 
characteristic adherence pattern on HEp-2 cells called 
aggregative adherence (AA), which is described as a 
stacked-brick configuration [92,94,114]. The plasmid- 
encoded aggregative adherence fimbriae I is known to 
mediate this AA phenotype [92,93]. A model of 
pathogenesis has been proposed that includes initial 
adherence, enhanced mucus production, and production of 
an EAEC cytotoxin [93]. The most frequent EAEC 
serogroups include O3, O15, O44, O77, O86, O92, O111, 
and O127 [35]. Disease outbreaks may be associated with 
food, but no single source has been implicated [35,93]. 
    The EIEC cause non-bloody diarrhea and dysentery 
similar to that caused by Shigella spp. [35,93]. This 
microorganism is able to invade and proliferate in colonic 
epithelial cells and is biochemically, genetically, and 
patho- physiologically related to Shigella spp. [12,93]. 
Genes necessary for invasion are carried on a 140- 
megadalton (MDa) plasmid called pInv [93,126]. The 
most frequent EIEC serogroups include O28ac, O29, 
O112, O124, O136, O143, O144, O152, O164, and O167 
[35]. Humans are the principal reservoir of EIEC, but the 
potential for person-to-person transmission is reduced 
because of a high infectious dose [53,93]. Most disease 
outbreaks are food- borne or water-borne [93,137]. 
  The DAEC cause diarrhea in young children from 1 to 5 
years of age, but little is known about the pathogenic 
features of DAEC-induced diarrhea [35,79,93]. By 
definition, DAEC does not produce LT or ST, does not 
possess the EPEC adherence factor plasmid, and does not 
invade epithelial cells [36,93]. However, this micro-
organism produces a characteristic diffusely-adherent 
pattern on HEp-2 cells that is distinguishable from that 
seen in the EAEC AA phenotype [35,36,93]. The most 
frequent DAEC serogroups include O1, O2, O21, and O75 
[35]. 
  The EHEC are a subset of the Shiga toxin-producing E. 
coli (STEC) that cause hemorrhagic colitis (HC) and the 
hemolytic uremic syndrome (HUS) in humans, produce 
one or more Shiga toxins (Stx), induce A/E lesions, and 
possess a 60-MDa plasmid called pO157 [93]. The EHEC 
serotypes most frequently associated with human disease 
include O26:H11, O103:H2, O111:H8, O145:H28, O157: 
H-, and O157:H7 [35,91]. Healthy cattle are the most 
important animal reservoir associated with human 
infection [52] although other healthy animals including 
sheep, goats, pigs, dogs, chickens, horses, deer, rats, and 
seagulls can also carry EHEC [10,24,35,52,73,108,144]. 
Enterohemorrhagic E. coli O157:H7
  E. coli O157:H7 is one of the most important serotypes of 
the STEC, because it causes most of the HUS disease. It 
was first described in 1977 by Konowalchuk et al. [71]. Its 
association with human disease was first reported during 
two outbreaks of HC in 1982 [109,146] and in sporadic 
cases of HUS in 1983 [66]. Since then, this microorganism 
has been associated with many disease outbreaks in the 
United States and in other countries around the world 
[35,93]. 
    Disease outbreaks are frequently associated with 
ingestion of food or water contaminated with bovine feces. 
Examples of these sources include undercooked ground 
beef, private or municipal water sources, and other food 
products, such as unpasteurized apple cider or milk, fresh 
vegetables, sprouts, and salami [8,50,134]. Visits to petting 
zoos, dairy farms, camping grounds where cattle have 
previously grazed, and recreational water sources have all 
resulted in infection [54,55]. Person-to-person transmis-
sion is also possible, especially in daycare centers [7,130]. 
Potential airborne transmission was recently reported after 
exposure to a contaminated building at an animal exhibit 
[140]. The various transmission routes may be explained 
by the very low infectious dose (10-100 organisms) of this 
microorganism. Therefore, minimal exposures can cause 
disease [35,93].
  Human infection with E. coli O157:H7 has been reported 
in at least 30 countries on six continents [35]. In the United 
States, 196 outbreaks or sporadic cases were documented 
through 1998, and the number of reported outbreaks has 
increased from two cases in 1982 to 42 cases in 1998 [35]. 
The medical costs of human illness caused by E. coli 
O157:H7 in the United States were estimated to be 
$0.3-$0.7 billion per year in 1993 [18]. A more recent 
estimation by the Center for Disease Control and Preven-
tion (CDC) reports that this microorganism accounts for 
73,480 illnesses, 2,168 hospitalizations, and 61 deaths per 
year in the United States [88]. About 85% of these cases are 
associated with food-borne transmission [88]. According 
to the outbreak surveillance data from the CDC, reported 
infections of E. coli O157:H7 increased annually starting 
in 1994, reaching a peak of 4,744 individual patients in 
1999 before decreasing to 2,544 patients in 2004 and 2,621 
in 2005. Large outbreaks or sporadic cases of E. coli O157: 
H7 have also been reported in Canada, Japan, and the 
United Kingdom [35]. However, accumulating data 
indicate that non-O157 EHEC infections may be more 
frequent than E. coli O157:H7 infections in continental 
Europe, Australia, and Latin America, indicating the 
possibility of differential geographic distribution [35,115]. 
  Patients infected with E. coli O157:H7 initially experi-
ence watery diarrhea; however, some individuals may be 
asymptomatic. Most cases are self-resolving within a 
week, but the disease sometimes progresses to HC 
(originally described as ‘all blood, no stool’) in one or two 
days, with severe abdominal cramps, and frequently no or 
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[17,64,93]. The disease evolves to HUS in 5-10% of HC 
patients, especially young children and the elderly. HUS is 
a life-threatening sequela defined by a triad of symptoms: 
acute renal failure, microangiopathic hemolytic anemia, 
and thrombocytopenia [5,100,140]. In adults, the infection 
may also lead to thrombotic thrombocytopenic purpura 
(TTP), a variant form of HUS. The pathological features of 
TTP are generally the same as those of HUS, but with the 
addition of fever and neurological symptoms such as 
lethargy, severe headache, convulsions, and encephalo-
pathy [100].
    There are no common distinguishable biochemical 
characteristics shared by EHEC strains [93]. However, 
there are some biochemical characteristics of E. coli 
O157:H7 that have been used for the isolation and 
identification of this serotype from clinical samples. An 
important characteristic is a delayed D-sorbitol 
fermentation (＞24 h). From 75% to 94% of other E. coli 
strains ferment D-sorbitol rapidly (＜24 h) [86,93]. This 
serotype also has the inability to produce β-glucuronidase, 
a feature that can be capitalized on in the laboratory 
through the use of synthetic molecules such as 
4-methyl-umbelliferyl-D-glucuronide, which fluoresce 
upon hydrolysis [133]. It has been demonstrated through 
the use of the MicroScan conventional Gram-negative 
identification system that more than 90% of the tested E. 
coli O157:H7 have one of two unique biochemical profiles 
that are not detected in other D-sorbitol negative E. coli 
strains [1]. However, the ID32E system showed that there 
were no unique profiles for E. coli O157:H7 [76]. 
Although no single biochemical profile is available for all 
E. coli O157:H7 isolates, the results indicate that E. coli 
O157:H7 possesses biochemical activities that are 
significantly divergent from generic E. coli. Examples 
include ornithine decarboxylase, arginine dehydrolase, 
urease, and 5-ketogluconate, and, to a lesser extent, 
fermentation of rhamnose, adonitol, D-arabitol, trehalose, 
and inositol [1,76]. One report shows that E. coli O157 
strains do not ferment rhamnose on agar plates, whereas 
60% of the non-sorbitol-fermenting E. coli belonging to 
other serogroups ferments rhamnose [128]. 
  The complete genome sequences of E. coli O157:H7 and 
E. coli K-12 reveal that these bacteria share a 4.1-Mb 
backbone of common sequences [104]. However, E. coli 
O157:H7 contains an additional 1.34-Mb region of 
genomic DNA that is not present in the E. coli K-12 
genome. This unique region contains approximately 1,400 
novel genes scattered throughout 177 discrete regions of 
DNA (＞50 bp in size) called O-islands. Moreover, E. coli 
O157:H7 is missing a 0.53-Mb region of genomic DNA 
that is present in the E. coli K-12 genome [31,104]. These 
comparisons indicate that lateral gene transfer likely 
occurred during the evolution of E. coli O157:H7. Clonal 
analyses suggest that E. coli O157:H7 descended from the 
non-toxigenic and less virulent E. coli O55:H7 [148,149]. 
The current model of the emergence of E. coli O157:H7 
from its prototype, E. coli O55:H7, is based on four 
sequential events: (i) acquisition of an stx2-containing 
bacteriophage in a single event and at a single site 
(probably  wrbA  encoding multimeric flavodoxin-like 
protein), (ii) splitting off of the clone leading to E. coli 
O157:H-, (iii) acquisition of the stx1-containing bacterio-
phage in a single site (probably yehV) by E. coli O157:H7, 
and (iv) loss of the ability to ferment D-sorbitol by E. coli 
O157:H7 [147]. 
Major virulence factors of E. coli O157:H7
Shiga toxins
  E.  coli O157:H7 produces one or more Stxs whose 
prototype is Stx produced by S. dysenteriae type I [90,93]. 
Stx1 is almost identical to Stx produced by S. dysenteriae 
type I, differing by only a single amino acid. Stx1 and Stx2 
share approximately 56% homology in their amino acid 
sequences, but they are antigenetically distinct [90]. A 
number of Stx2 variants such as Stx2c, Stx2d, and Stx2e 
have been identified, and they share 84-99% amino acid 
sequence homology with Stx2 [90]. Stx2c and Stx2d are 
associated with HC and HUS in humans, whereas Stx2e is 
primarily associated with swine edema disease. Stx2d is 
known to be activated by an elastase present in human 
mucus [134]. Stxs belong to an AB5 toxin family 
consisting of one enzymatically active A subunit and five 
identical receptor-binding B subunits. All the genes for the 
Stx family are encoded as a single transcriptional unit by 
bacteriophages, except for the chromosomally-encoded 
Stx2e [90,100]. However, the Stx B-subunit gene has a 
stronger ribosomal binding site than that of the A-subunit 
gene, resulting in increased translation of B subunits [100]. 
This may help to maintain a 1：5 A/B subunit stoichiometry 
of the holotoxin. 
  To cause disease, Stxs must be translocated from the 
intestine to the blood stream. The underlying mechanisms 
are not clearly understood [35,93,100]. Patients infected 
with E. coli O157:H7 frequently shed fecal leukocytes, and 
although inflammation may play a role, transient epithelial 
damage occurs during migration of leukocytes across the 
intestinal epithelium to the lumen [125,134]. These 
eventually cause toxin uptake across the intestinal 
epithelium  in vitro [57]. Furthermore, generalized 
intestinal inflammation caused by the infection may 
promote systemic Stx uptake. Stxs are associated with 
vascular damage in the colon, and LPS may also play a role 
in intestinal inflammation during E. coli O157:H7 
infection [2,123]. 
  The receptors for Stxs are globotriaosylceramide (Gb3) 
or globotetra-osylceramide (Gb4), which are both 
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[35,93,100]. Both Stx1 and Stx2 bind to Gb3, whereas 
Stx2e binds to Gb4. Gb3 is expressed on a variety of 
epithelial and endothelial cells in humans and animals 
[83,142]. After receptor-mediated endocytosis, Stxs move 
to the endoplasmic reticulum via the Golgi network and 
Golgi apparatus by retrograde transport [113]. During 
retrograde transport, the A subunit is cleaved by furin, a 
calcium-sensitive serine protease in the Golgi apparatus. In 
the endoplasmic reticulum, it is thought that the disulfide 
bond in the A subunit is reduced and the released A1 
fragment is translocated into the cytoplasm [96]. The A1 
fragment has RNA N-glycosidase activity that can 
irreversibly depurinate a specific adenine (A4324) residue 
from the 28S rRNA of the 60S ribosome [39]. This process 
prevents binding of elongation factor I-dependent 
aminoacyl- tRNA, inhibits protein synthesis, and results in 
host cell death [95]. 
  In addition to their RNA N-glycosidase activity, Stxs can 
induce apoptosis in HEp-2 or HeLa cells [21]. Stx1 or Stx2 
treatment of HEp-2 cells results in up-regulated expression 
of the proapoptotic Bax protein [28]. Overexpression of 
Bcl-2 protein protects cells from Stx-induced apoptosis 
[21,61]. Interestingly, the Stx1 B-subunit itself can cause 
apoptosis in HEp-2 cells, although higher doses are needed 
compared to holotoxin [61]. This indicates that the B 
subunit plays a role in signal transduction, as well as in 
toxin binding. Recently, it was demonstrated that Stxs are 
able to reduce bovine leukemia virus replication in vitro 
and  in vivo [41-44]. Virus-infected cells are able to 
internalize the toxins by simple diffusion through virus- 
induced permeable cell membranes. Although the 
underlying mechanism is unknown, this may explain the 
carriage of intestinal STEC by all cattle. 
The locus of enterocyte effacement
  Formation of A/E lesions is a unique characteristic of 
EHEC/EPEC pathogenesis [46]. The A/E lesions are 
characterized by the loss of microvilli, an intimate 
adherence of bacteria adjacent to the host cell membrane, 
and the generation of an organized cytoskeletal structure 
containing filamentous actin beneath adherent bacteria, 
which is called an actin pedestal [33]. The genetic element 
responsible for the A/E lesions is called the locus of 
enterocyte effacement (LEE), and it is a well-known 
pathogenicity island present in EPEC, EHEC, Hafnia 
alvei,  Citrobacter rodentum, and other attaching and 
effacing E. coli that are pathogenic in animal species [46]. 
  The complete sequence of the LEE in E. coli O157:H7 
reveals that the O157:H7 LEE is 43,359-bp in size, which 
is larger than the 35,624-bp LEE in EPEC [31,38,103]. A 
7.5-kb putative prophage near the selC end of the LEE 
locus is responsible for most of the size difference. The 
G+C content in the O157:H7 LEE is 40.9%, much lower 
than that of the E. coli K-12 genome (average 50.8%). The 
prophage base composition is 51.7% G+C, whereas the 
remainder of the LEE element is 39.6% G+C. This 
indicates that the O157:H7 LEE results from horizontal 
gene transfer from other species. The O157:H7 LEE 
encodes 54 open reading frames (ORFs). Thirteen ORFs 
are located on the putative phage, and 41 ORFs correspond 
to those of EPEC LEE in the order and number of genes 
[46,103]. 
  The LEE region contains three segments encoding five 
operons [46,103]: (i) the first segment includes the LEE1, 
LEE2, and LEE3 operons that encode the genes for the type 
III secretion system (TTSS), (ii) the second segment 
includes the translocated intimin receptor (Tir) (LEE5) 
operon that encodes the genes for bacterial adhesion such 
as intimin and the Tir, and (iii) the third segment includes 
the LEE4 operon that encodes the genes for the E. coli 
secreted proteins, such as EspA, EspB, and EspD. The 
EspABD complex forms the translocation apparatus 
functioning to transfer the effector proteins of the TTSS. A 
recent study demonstrated that EspB itself is an effector 
protein of the TTSS, which are required for microvilli 
effacement or suppression of phagocytosis during 
infection [59]. Interestingly, the O157:H7 LEE does not 
induce the A/E lesions in the E. coli K-12 background, 
whereas the EPEC LEE does [38]. This indicates that there 
are some differences between the O157:H7 LEE and the 
EPEC LEE in terms of function and regulation. The 
regulatory mechanisms of the LEE genes, as well as 
environmental signals, are known to be complicated and 
are well reviewed in the reference [89]. 
The pO157
    Initial profiling of the plasmids present in E. coli 
O157:H7 demonstrated the presence of multiple plasmids 
and the high prevalence of the pO157. The plasmid pO157 
was found in 99% of 107, 100% of 100, and 100% of 88 
clinical isolates of E. coli O157:H7 from humans [80,98, 
107]. The subsequent epidemiological studies suggest that 
almost all E. coli O157:H7 strains possess this plasmid 
[93]. A pO157-like plasmid is also present in O26:H11 
strains and in most STEC isolates from humans and 
animals [93,118]. However, its biological significance in 
infection is unknown. 
  Previous  in vivo and in vitro studies have reported 
conflicting results on the role of the plasmid in adherence 
to epithelial cells [48,65,93,132,139,143]. Karch et al. [65] 
first reported that the pO157 is associated with the 
expression of fimbriae that enhance bacterial adherence to 
epithelial cells. However, supporting data have not been 
shown yet. Other studies have shown that the plasmid has 
no effect on adhesion or reduced adherence [93]. Similarly, 
in vivo studies using animal models such as mouse, rabbit, 
and gnobiotic piglet did not help to define the biological 
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histopathology, or the fecal shedding patterns of E. coli 
O157:H7. The absence of suitable animal models may be 
partially responsible for these conflicting results [93]. 
Furthermore, a study showed that the pO157 is somehow 
associated with the suppression of exopolysaccharide 
production in E. coli O157:H7 [48,62].
  Recently, the complete nucleotide sequence of the pO157 
was determined [16]. It revealed that the plasmid is a very 
stable, 92-kb F-like plasmid and has a heterogeneous 
mosaic structure with seven insertion sequence elements 
located near the virulence-related segments. The pO157 
contains 100 ORFs, of which only 19 have been previously 
characterized. These include a type II secretory system 
(etpC-etpO) [116], enterohemolysin (hlyA-D) [117], 
catalase-peroxidase (katP) [13], serine protease (espP) 
[14], lymphocyte inhibitory factor (lifA/efa) [60], a 
putative adhesin (toxB) [131], and a recently described C1 
esterase inhibitor metalloprotease (StcE) [74]. However, 
the biological significance of these putative virulence 
factors was not demonstrated.
Pathologenesis of E. coli O157:H7
  There are many requirements for an E. coli O157:H7 
infection to occur, involving complex interactions between 
bacterial and host factors. Ingested bacteria must survive in 
the acidic environment of the stomach and then compete 
with other gut microflora to establish intestinal coloniza-
tion. Once colonization has occurred, the bacteria produce 
Stxs in the intestinal lumen, which must be absorbed by the 
intestinal epithelium and must move to the blood stream. A 
three-stage model for EPEC and EHEC has been proposed, 
including (i) initial adherence, (ii) signal transduction, and 
(iii) intimate adherence [93,100]. 
Initial adherence
  Although accumulating data show that intimin is clearly 
associated with bacterial adherence in the later stages of 
pathogenesis [27,35,93], it is still unclear which factors are 
involved in initial adherence. Nonetheless, some adherence- 
associated factors have been characterized. 
  Karch  et al. [65] reported a fimbrial adhesin whose 
expression was associated with the presence of the pO157. 
They showed that the fimbrial adhesin mediates bacterial 
attachment to Henle407, but not to HEp-2 cells. Further 
studies have failed to support these findings, and recent 
sequencing data reveal that the pO157 is not predicted to 
encode a fimbrial gene cluster. This indicates that this 
fimbrial adhesin may be encoded on the chromosome. In-
creasing evidence indicates that lipopolysaccharide (LPS) 
is associated with bacterial adhesion, probably through an 
indirect mechanism rather than through a direct 
mechanism [11,26]. It has been reported that anti-LPS 
antibody can block bacterial adherence to Henle407 cells, 
whereas the pretreatment of Henle407 cells with LPS 
cannot block bacterial adherence [99]. Furthermore, a 
hyper-adherent phenotype, observed with HEp-2 cells, is 
an  E. coli O157:H7 LPS-deficient mutant lacking the 
O-polysaccharide side chain [11,26]. Although this 
increased adhesion may be due to autoaggregation and 
rapid sedimentation of strains lacking the O-antigen [120], 
it seems that LPS masks adhesive structures present on the 
bacterial surface or that bacterial surface properties such as 
hydrophobicity are altered by the absence of LPS. Sherman 
and Soni [122] showed that outer membrane (OM) 
preparations from an E. coli O157:H7 isolate inhibit 
bacterial adherence to HEp-2 cells. Further analysis showed 
that antibodies specific for a 94-kDa OM protein inhibit 
adhesion and that this protein is immunologically distinct 
from intimin [121]. Tarr et al. [131] described a 
chromosomally encoded Iha, IrgA homologous adhesin in 
E. coli O157: H7, which is an OM protein conferring an 
adherence phenotype with HeLa cells. This gene shows 
homology to the IrgA gene of Vibrio cholerae, which encodes 
an iron-regulated protein [131]. Iha is located adjacent to 
the tellurite resistant loci and is therefore designated TAI 
(tellurite resistance- and adherence-conferring island). 
This region is highly conserved in distantly related 
pathogenic E. coli, but not in non-toxigenic E. coli O55: 
H7, sorbitol-fermenting STEC O157:H-, or laboratory E. 
coli strains [131]. 
  ToxB is a large 362-kDa OM protein encoded on the 
pO157 [132]. This protein shares sequence similarity with 
the large Clostridium toxin family proteins such as the 
EPEC LifA protein [69] and the Efa-1 protein that has been 
implicated as an adhesin in non-O157 EHEC [118]. ToxB 
plays a role in full adherence of E. coli O157:H7 to Caco-2 
cells by facilitating the secretion of TTSS proteins [132]. 
  Recently, a hyper-adherent phenotype was observed in 
the E. coli O157:H7 tdcA mutant, which is a regulator of 
the  tdc  operon responsible for transport and anaerobic 
degradation of L-threonine [136]. Interestingly, in this 
mutant, an OM protein A (OmpA) was differentially 
expressed. OmpA has been associated with many 
functions, such as porin activity, mediation of conjugation, 
serum resistance, and bacterial invasion [136]. However, 
in E. coli O157:H7, OmpA seems to be an adherence factor 
that mediates bacterial adherence to Caco-2 cells and HeLa 
cells. 
  McKee and O'Brien [87] described a ‘log jam’ adherence 
phenotype in E. coli O157:H7, in which bacteria adhered 
to, and lined up at, the junction between HCT-8 cells, but 
not HEp-2 cells. This adherence pattern is observed in 
other pathogenic E. coli, as well as in E. coli O157:H7, and 
therefore may represent a basal adherence mechanism 
allowing E. coli to adhere to the intestinal epithelium. 
  A recent study has characterized an endogenous host cell 
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intimin may also promote initial adherence of E. coli 
O157:H7 [124]. 
Signal transduction
  The O157:H7 LEE encodes the TTSS required for the 
contact-dependent translocation of bacterial proteins into 
host cells [19,46,135]. The effector proteins are also 
encoded on the LEE and include the E. coli secreted 
proteins EspA, EspB, EspD, EspF, EspG, mitochondria- 
associated protein, and Tir [19,110]. EspA forms a 
filamentous cylindrical structure for the export of EspB 
and EspD [37,70]. EspB/EspD are thought to transit 
through the EspA filament to form a pore (or translocon) in 
the host membrane and also to deliver other virulence 
factors into the cells [58]. For example, a functional EspA 
filament and EspB/D translocon are required for 
translocation of Tir. In addition, the targeting and function 
of other TTSS-secreted proteins have been reviewed in 
detail in the reference [110].
  Compared to EPEC, pedestal formation by E. coli O157: 
H7 is more complex and less well characterized [19]. 
However, E. coli O157:H7 forms pedestals independently 
of Nck (an adaptor protein containing src homology 2 and 
3 domains), because E. coli O157:H7 does not recruit Nck 
to the site of actin polymerization, and it can form pedestals 
on cell lines that do not express Nck [51]. Moreover, 
Nck-independent actin signaling by E. coli O157:H7 
requires translocation of one or more bacterial factors in 
addition to Tir [29]. The combination of Tir and other 
factors promotes recruitment and activation of neuronal 
Wiskott- Aldrich syndrome protein (N-WASP) by an 
unidentified mechanism. N-WASP then stimulates Arp2/3 
(a heptameric actin-related protein 2/3)-based actin 
nucleation [19,111]. 
  Although EPEC and EHEC contain highly conserved 
LEE regions and form similar actin pedestals, it seems that 
they induce different Tir-based signaling in the host cells. 
For example, the EPEC Tir is phosphorylated on a tyrosine 
residue (Tyr474) in its C-terminal cytoplasmic domain, 
whereas the EHEC Tir is not [30,67]. Similarly, 
mammalian adaptor proteins Grb2 and CrkII are able to 
localize to EPEC pedestals, but not to EHEC pedestals 
[49]. Localization of these proteins depends on EPEC Tir 
tyrosine phosphorylation. Additionally, EHEC Tir is not 
functional for actin signaling when expressed in EPEC 
[29,67]. These data indicate that the mechanism of actin 
signal transduction is different in EPEC and in EHEC.
Intimate adherence
  The genes involved in intimate adherence are eae and tir 
[46]. Studies on E. coli O157 intimin have shown that it can 
act as an adhesin for bacterial adherence to HEp-2 cells 
[34,84].  In vivo studies using ruminants and gnobiotic 
piglets have demonstrated that intimin-deficient E. coli 
O157:H7 mutants are less virulent than the parent strain 
and are less able to colonize the intestines of these animals 
[27,34]. In addition, the eae gene of EPEC is functionally 
homologous to the EHEC eae gene because it restores full 
virulence to the O157:H7 eae mutant [34]. Further studies 
in gnobiotic piglets have shown that an E. coli O157:H7 
intimin-negative mutant expressing the EPEC intimin 
adheres to different bowel sites, suggesting that the EPEC 
and  E. coli O157:H7 intimins have different receptor 
binding specificities in this model [138]. 
  Although of similar molecular weight, the EPEC and 
EHEC intimins show some differences. Overall, the two 
proteins are 83% homologous at the amino acid level, with 
the first 704 amino acids sharing 94% homology and the 
remaining C-terminal residues sharing only 49% 
homology [153]. The C-terminus is the receptor binding 
region, and differences in this region may explain the 
different tissue tropisms of the EPEC and EHEC intimins. 
The different tissue tropisms are dependent on the ability 
of intimin to bind to endogenous host cell receptors, as well 
as to Tir [45,47]. Recent data show that intimin can bind to 
both Tir and to host receptors [124]. Binding to Tir occurs 
through two Ig-like regions, whereas binding to the host 
receptors occurs through a lectin-like region. 
Environmental survival of E. coli O157:H7
  In general, Gram-negative bacteria have an OM separated 
from the inner membrane by a periplasmic space. This 
arrangement allows cells to filter and sense the extra-
cellular environment, as well as export virulence factors to 
the exterior [106]. Among the structural components, the 
OM is very important in bacterial physiology. In enteric 
Gram- negative bacteria, the OM acts as a strong physical 
and permeability barrier that protects bacteria from host 
defense factors such as bile salts, digestive enzymes, and 
immune factors, in addition to many antibiotics [25,129, 
141]. 
  E. coli O157:H7 thrives in diverse environments−from 
soil, sewage, and water ecosystems to the host 
gastrointestinal tract. This microorganism can survive for 
long periods of time in water, especially at cold 
temperatures, and can enter a viable but non-culturable 
state [145]. E. coli O157:H7 was shown to survive for more 
than 8 months in a farm water trough, and the surviving 
cells proved to be infectious to calves [77]. E. coli 
O157:H7 can survive in raw (not composted) bovine or 
ovine feces for 21 months and retain its virulence traits, 
such as Stx production [72]. A recent study showed that E. 
coli O157:H7 survives and replicates in a common 
environmental protozoan, Acanthamoeba polyphaga [6]. 
Since protozoa are widely distributed in soil, water, and 
fecal slurry, they seem to be an important transmission 
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  E.  coli O157:H7 must pass through the acidic 
environment of the stomach to establish an infection in the 
host GIT. Three systems in E. coli O157:H7 are involved in 
acid tolerance: an acid-induced oxidative system, an 
acid-induced arginine-dependent system, and a glutamate- 
dependent system [75]. The oxidative system is less 
effective in protecting the organism from acid stress than 
are the arginine- and glutamate-dependent systems [82]. 
The alternate sigma factor, RpoS, is required for oxidative 
acid tolerance, but is only partially involved with the other 
two systems. Once induced, acid resistance is stable during 
storage at 4
oC (＞28 days) [35]. Stationary phase bacteria 
are more than 1,000 times more resistant to acid than 
exponentially growing organisms and do not need prior 
exposure to low pH to exhibit resistance. More 
importantly, acid resistance also increases resistance to 
other environmental stresses. Acid resistance-induced 
cells can have increased tolerance to heating, radiation, and 
antimicrobials [15,112]. An E. coli O157:H7 rpoS mutant 
is significantly less tolerant to acid, heat, and high salt 
conditions than is the parent strain [22,105]. In addition, a 
recent study suggests that the ability to produce 
exopolysaccharide in E. coli O157:H7 is associated with 
bacterial tolerance against heat and acid [85]. Interestingly, 
heat stress can induce the alteration of membrane lipid 
composition in E. coli O157:H7, which also affects 
virulence gene expression [154]. 
  The tolerance of E. coli O157:H7 to varied environments 
likely requires differential gene expression. DNA 
topological changes have been suggested to explain 
differential gene expression, especially in response to 
various environments with extremes of temperature, pH, 
osmolarity, and anaerobiosis [4,40]. An example is an 
intrinsically curved DNA [97,101,102]. A recent study 
demonstrated that the pO157 ecf operon is thermoregulated 
through an intrinsically curved DNA called BNT2, which 
is present on its promoter upstream regulatory region 
[152]. Differential expression of the genes encoding in this 
operon has been proposed to be responsible for the 
structural modification of E. coli O157:H7 LPS, which 
may enhance bacterial survival in certain ex vivo and in 
vivo environments [63,68,81,127,151,152]. 
Treatment and vaccine development
  Therapeutic strategies can be categorized as limiting the 
severity and duration of gastrointestinal symptoms and 
preventing systemic complications such as HUS [100]. 
There is controversy about the use of antibiotics. Although 
it was reported that early treatment with fosfomycin 
reduced the risk of HUS during a large outbreak in Japan in 
1996, several studies have failed to recommend antibiotic 
treatment [93,150]. It may be possible that antibiotics 
allow overgrowth of E. coli O157:H7 by killing other gut 
microflora. Antibiotics may also cause bacterial cell lysis 
that could increase the systemic absorption of the toxin by 
increasing the amount of membrane-free Stx in the 
intestine [23]. Furthermore, antibiotics such as trimethoprim- 
sulfamethoxazole and ciprofloxacin (bacterial DNA 
synthesis inhibitors) increase the amount of free Stx in the 
culture medium [100]. In addition to antibiotic therapy, an 
alternative therapeutic strategy that has been investigated 
is in vivo binding or neutralization of Stx. This strategy 
may limit the severity or duration of disease, but will not 
reduce bacterial transmission [100]. Agents such as 
Synsorb-Pk, which consists of the oligosaccharide 
component of Gb3 covalently linked via an 8-carbon 
spacer to silica particles derived from diatomaceous earth, 
have been administrated to patients with HC in hopes of 
preventing the development of HUS, but have met with 
limited success [3]. Current treatment of renal disease 
includes dialysis, hemofiltration, transfusion of packed 
erythrocytes, and platelet infusions. Some patients that 
survive severe disease may still need renal transplantation 
[93]. There is no available vaccine to prevent infection by 
E. coli O157:H7, but current vaccine development studies 
using animal models have focused on three main areas: (i) 
vaccination against colonization factors such as intimin, 
(ii) vaccination against LPS, and (iii) vaccination with Stx 
subunits or toxoids [56,93]. 
Concluding remarks
  E. coli O157:H7 are highly infectious to humans and 
animals and can tolerate diverse environments well−from 
nutrient-dilute water to adverse gastrointestinal tracts. The 
pathogenesis of this bacterium is believed to be multi-
factorial, because any single functional mutation of the 
previously defined virulence factors is not completely 
attenuated. Therefore, further studies of the mechanisms 
by which E. coli O157:H7 thrives and colonizes ex vivo or 
in vivo during infection would provide significant 
opportunities for developing a new vaccine or therapeutics 
to prevent or ameliorate bacterial infection. 
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